407 related articles for article (PubMed ID: 12790774)
1. Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention.
Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura S; Yue W; Berstein L
Endocr Relat Cancer; 2003 Jun; 10(2):111-30. PubMed ID: 12790774
[TBL] [Abstract][Full Text] [Related]
2. Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells.
Song RX; Santen RJ; Kumar R; Adam L; Jeng MH; Masamura S; Yue W
Mol Cell Endocrinol; 2002 Jul; 193(1-2):29-42. PubMed ID: 12160999
[TBL] [Abstract][Full Text] [Related]
3. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity.
Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura A; Lawrence J; Berstein L; Yue W
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S61-73. PubMed ID: 16113100
[TBL] [Abstract][Full Text] [Related]
4. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment.
Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura S; Lawrence J; MacMahon LP; Yue W; Berstein L
J Steroid Biochem Mol Biol; 2005 May; 95(1-5):155-65. PubMed ID: 16024245
[TBL] [Abstract][Full Text] [Related]
5. Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells.
Santen RJ; Song RX; Masamura S; Yue W; Fan P; Sogon T; Hayashi S; Nakachi K; Eguchi H
Adv Exp Med Biol; 2008; 630():19-34. PubMed ID: 18637482
[TBL] [Abstract][Full Text] [Related]
6. Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer.
Santen RJ; Song RX; Zhang Z; Yue W; Kumar R
Clin Cancer Res; 2004 Jan; 10(1 Pt 2):337S-45S. PubMed ID: 14734489
[TBL] [Abstract][Full Text] [Related]
7. Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients.
Santen R; Jeng MH; Wang JP; Song R; Masamura S; McPherson R; Santner S; Yue W; Shim WS
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):115-25. PubMed ID: 11850215
[TBL] [Abstract][Full Text] [Related]
8. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
9. Estrogen signaling: An emanating therapeutic target for breast cancer treatment.
Saha T; Makar S; Swetha R; Gutti G; Singh SK
Eur J Med Chem; 2019 Sep; 177():116-143. PubMed ID: 31129450
[TBL] [Abstract][Full Text] [Related]
10. Adaptive hypersensitivity following long-term estrogen deprivation: involvement of multiple signal pathways.
Yue W; Wang JP; Conaway MR; Li Y; Santen RJ
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):265-74. PubMed ID: 14623520
[TBL] [Abstract][Full Text] [Related]
11. Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer.
Weigel MT; Ghazoui Z; Dunbier A; Pancholi S; Dowsett M; Martin LA
Breast Cancer Res; 2012 May; 14(3):R78. PubMed ID: 22608253
[TBL] [Abstract][Full Text] [Related]
12. Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation.
Martin LA; Farmer I; Johnston SR; Ali S; Dowsett M
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S75-84. PubMed ID: 16113101
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of aromatase: insights from recent studies.
Santen RJ
Steroids; 2003 Sep; 68(7-8):559-67. PubMed ID: 12957661
[TBL] [Abstract][Full Text] [Related]
14. Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation.
Chan CM; Martin LA; Johnston SR; Ali S; Dowsett M
J Steroid Biochem Mol Biol; 2002 Aug; 81(4-5):333-41. PubMed ID: 12361723
[TBL] [Abstract][Full Text] [Related]
15. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation.
Martin LA; Farmer I; Johnston SR; Ali S; Marshall C; Dowsett M
J Biol Chem; 2003 Aug; 278(33):30458-68. PubMed ID: 12775708
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells.
Jeng MH; Shupnik MA; Bender TP; Westin EH; Bandyopadhyay D; Kumar R; Masamura S; Santen RJ
Endocrinology; 1998 Oct; 139(10):4164-74. PubMed ID: 9751496
[TBL] [Abstract][Full Text] [Related]
17. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis.
Yue W; Santen RJ; Wang JP; Li Y; Verderame MF; Bocchinfuso WP; Korach KS; Devanesan P; Todorovic R; Rogan EG; Cavalieri EL
J Steroid Biochem Mol Biol; 2003 Sep; 86(3-5):477-86. PubMed ID: 14623547
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
19. Aromatase and breast cancer.
Brodie A; Sabnis G; Jelovac D
J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):97-102. PubMed ID: 17113978
[TBL] [Abstract][Full Text] [Related]
20. The potential of aromatase inhibitors in breast cancer prevention.
Santen RJ; Yue W; Naftolin F; Mor G; Berstein L
Endocr Relat Cancer; 1999 Jun; 6(2):235-43. PubMed ID: 10731115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
